The variability in tumor response rates across age groups and studies suggests the importance of tailored treatment approaches and further investigation into predictive biomarkers that could better inform therapeutic decisions in NF2 patients, particularly among younger patients where the long-term efficacy and safety of bevacizumab remain areas of active research. The gene discussed is NF2; the disease is neoplasm.